{"id":944,"date":"2020-01-10T17:28:24","date_gmt":"2020-01-10T17:28:24","guid":{"rendered":"https:\/\/www.sfj-pharma.com\/?p=944"},"modified":"2021-02-10T18:37:53","modified_gmt":"2021-02-10T18:37:53","slug":"phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2","status":"publish","type":"post","link":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/","title":{"rendered":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452"},"content":{"rendered":"\n<h1 class=\"wp-block-heading\">PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452<\/h1>\n\n\n\n<p><a href=\"https:\/\/investors.phasebio.com\/node\/7356\/pdf\" target=\"_blank\" rel=\"noreferrer noopener\">PDF Version<\/a><\/p>\n\n\n\n<p><em>PhaseBio to receive up to&nbsp;$120 million&nbsp;in development funding<\/em><br><\/p>\n\n\n\n<p><em>PhaseBio retains exclusive worldwide commercial rights to PB2452<\/em><\/p>\n\n\n\n<p>MALVERN, Pa.&nbsp;and&nbsp;SAN DIEGO,&nbsp;Jan. 10, 2020&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;PhaseBio Pharmaceuticals, Inc.&nbsp;(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced a financing and co-development collaboration with&nbsp;SFJ Pharmaceuticals&nbsp;to support the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor.&nbsp;SFJ Pharmaceuticals&nbsp;is a global drug development company backed by Blackstone Life Sciences and Abingworth.<\/p>\n\n\n\n<p>The collaboration between SFJ and PhaseBio will support the global development of PB2452, which is designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations. Under the terms of the agreement, SFJ has agreed to fund up to&nbsp;$120 million&nbsp;to support the clinical development of PB2452 and to assume a central role in global clinical development and regulatory activities for PB2452 outside&nbsp;the United States. SFJ will fund up to&nbsp;$90 million&nbsp;of development expenses through the end of 2021 and up to an additional&nbsp;$30 million&nbsp;based on PhaseBio meeting specific, pre-defined clinical milestones for PB2452.<\/p>\n\n\n\n<p><a href=\"https:\/\/investors.phasebio.com\/news-releases\/news-release-details\/phasebio-announces-financing-and-co-development-collaboration\">Read Full Report<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 PDF Version PhaseBio to receive up to&nbsp;$120 million&nbsp;in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa.&nbsp;and&nbsp;SAN DIEGO,&nbsp;Jan. 10, 2020&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;PhaseBio Pharmaceuticals, Inc.&nbsp;(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on&#8230;<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[103],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 - SFJ Pharmaceuticals<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 - SFJ Pharmaceuticals\" \/>\n<meta property=\"og:description\" content=\"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 PDF Version PhaseBio to receive up to&nbsp;$120 million&nbsp;in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa.&nbsp;and&nbsp;SAN DIEGO,&nbsp;Jan. 10, 2020&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;PhaseBio Pharmaceuticals, Inc.&nbsp;(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\" \/>\n<meta property=\"og:site_name\" content=\"SFJ Pharmaceuticals\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-10T17:28:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-10T18:37:53+00:00\" \/>\n<meta name=\"author\" content=\"khateam\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"khateam\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\"},\"author\":{\"name\":\"khateam\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\"},\"headline\":\"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452\",\"datePublished\":\"2020-01-10T17:28:24+00:00\",\"dateModified\":\"2021-02-10T18:37:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\"},\"wordCount\":231,\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\",\"url\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\",\"name\":\"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 - SFJ Pharmaceuticals\",\"isPartOf\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\"},\"datePublished\":\"2020-01-10T17:28:24+00:00\",\"dateModified\":\"2021-02-10T18:37:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.sfj-pharma.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#website\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"name\":\"SFJ Pharmaceuticals\",\"description\":\"Resources for Accelerated Clinical Development\",\"publisher\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.sfj-pharma.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#organization\",\"name\":\"SFJ Pharmaceuticals\",\"url\":\"https:\/\/www.sfj-pharma.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"contentUrl\":\"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552\",\"width\":750,\"height\":205,\"caption\":\"SFJ Pharmaceuticals\"},\"image\":{\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc\",\"name\":\"khateam\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g\",\"caption\":\"khateam\"},\"sameAs\":[\"https:\/\/www.sfj-pharma.com\"],\"url\":\"https:\/\/www.sfj-pharma.com\/author\/khateam\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 - SFJ Pharmaceuticals","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/","og_locale":"en_US","og_type":"article","og_title":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 - SFJ Pharmaceuticals","og_description":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 PDF Version PhaseBio to receive up to&nbsp;$120 million&nbsp;in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa.&nbsp;and&nbsp;SAN DIEGO,&nbsp;Jan. 10, 2020&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;PhaseBio Pharmaceuticals, Inc.&nbsp;(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on...","og_url":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/","og_site_name":"SFJ Pharmaceuticals","article_published_time":"2020-01-10T17:28:24+00:00","article_modified_time":"2021-02-10T18:37:53+00:00","author":"khateam","twitter_card":"summary_large_image","twitter_misc":{"Written by":"khateam","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/#article","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/"},"author":{"name":"khateam","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc"},"headline":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452","datePublished":"2020-01-10T17:28:24+00:00","dateModified":"2021-02-10T18:37:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/"},"wordCount":231,"publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/","url":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/","name":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 - SFJ Pharmaceuticals","isPartOf":{"@id":"https:\/\/www.sfj-pharma.com\/#website"},"datePublished":"2020-01-10T17:28:24+00:00","dateModified":"2021-02-10T18:37:53+00:00","breadcrumb":{"@id":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.sfj-pharma.com\/phasebio-announces-financing-and-co-development-collaboration-with-sfj-pharmaceuticals-for-pb2452-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sfj-pharma.com\/"},{"@type":"ListItem","position":2,"name":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452"}]},{"@type":"WebSite","@id":"https:\/\/www.sfj-pharma.com\/#website","url":"https:\/\/www.sfj-pharma.com\/","name":"SFJ Pharmaceuticals","description":"Resources for Accelerated Clinical Development","publisher":{"@id":"https:\/\/www.sfj-pharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sfj-pharma.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sfj-pharma.com\/#organization","name":"SFJ Pharmaceuticals","url":"https:\/\/www.sfj-pharma.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/","url":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","contentUrl":"https:\/\/secureservercdn.net\/198.71.233.213\/c59.835.myftpupload.com\/wp-content\/uploads\/2020\/12\/SFJ-Logo-Final-RGB.png?time=1666279552","width":750,"height":205,"caption":"SFJ Pharmaceuticals"},"image":{"@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/049145e1c21636813c9d02a662ef41cc","name":"khateam","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sfj-pharma.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9bf77b4329fc605a71e83152d4944475?s=96&d=mm&r=g","caption":"khateam"},"sameAs":["https:\/\/www.sfj-pharma.com"],"url":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"}]}},"rttpg_featured_image_url":null,"rttpg_author":{"display_name":"khateam","author_link":"https:\/\/www.sfj-pharma.com\/author\/khateam\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.sfj-pharma.com\/category\/news\/\" rel=\"category tag\">News<\/a>","rttpg_excerpt":"PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals\u00ae for PB2452 PDF Version PhaseBio to receive up to&nbsp;$120 million&nbsp;in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa.&nbsp;and&nbsp;SAN DIEGO,&nbsp;Jan. 10, 2020&nbsp;(GLOBE NEWSWIRE) &#8212;&nbsp;PhaseBio Pharmaceuticals, Inc.&nbsp;(Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on...","_links":{"self":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/944"}],"collection":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/comments?post=944"}],"version-history":[{"count":1,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/944\/revisions"}],"predecessor-version":[{"id":7073,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/posts\/944\/revisions\/7073"}],"wp:attachment":[{"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/media?parent=944"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/categories?post=944"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sfj-pharma.com\/wp-json\/wp\/v2\/tags?post=944"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}